Cargando…

Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals

SIMPLE SUMMARY: In the present study we investigated the ability of different non-invasive scoring systems (i.e., Forns index, APRI, FIB-4, ALBI, and aMAP) to predict hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis treated with direct-acting antivirals f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caviglia, Gian Paolo, Troshina, Giulia, Santaniello, Umberto, Rosati, Giulia, Bombaci, Francesco, Birolo, Giovanni, Nicolosi, Aurora, Saracco, Giorgio Maria, Ciancio, Alessia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834182/ https://www.ncbi.nlm.nih.gov/pubmed/35159094 http://dx.doi.org/10.3390/cancers14030828

Ejemplares similares

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals
por: Armandi, Angelo, et al.
Publicado: (2022)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
por: Olivero, Antonella, et al.
Publicado: (2022)

Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients
por: Pietrosi, Giada, et al.
Publicado: (2020)

Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis
por: Rosso, Chiara, et al.
Publicado: (2022)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis
por: An, JiHyun, et al.
Publicado: (2022)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
por: Riaz, Hafiza Arooba, et al.
Publicado: (2023)

Need to Face Liver Cirrhosis after HCV Cure with Antivirals
por: Soriano, Vicente, et al.
Publicado: (2017)

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy
por: Cusato, Jessica, et al.
Publicado: (2022)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

The Impact of Mevastatin on HCV Replication and Autophagy of Non-Transformed HCV Replicon Hepatocytes Is Influenced by the Extracellular Lipid Uptake
por: Vescovo, Tiziana, et al.
Publicado: (2019)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

A Review of HDV Infection
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study
por: Ciancio, Alessia, et al.
Publicado: (2023)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
por: Mihai, Florin, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort
por: Quaranta, Maria Giovanna, et al.
Publicado: (2021)

A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
por: Kondili, Loreta A., et al.
Publicado: (2022)

354. Efficacy of Second-Generation Direct Acting Antivirals in the Setting of HCV/HIV Co-infection and Cirrhosis: A Review of Real-World Treatment Experiences
por: Saba, Nicholas, et al.
Publicado: (2019)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy
por: Caviglia, Gian Paolo, et al.
Publicado: (2012)

Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals
por: Nguyen, Kelvin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ocdvt8pn0a26266s9rugmc8708